Disruption of splicing patterns due to mutations of genes coding
splicing factors in
tumors represents a potential source of
tumor neoantigens, which would be both public (shared between patients) and
tumor-specific (not expressed in normal tissues). In this study, we show that mutations of the
splicing factor SF3B1 in
uveal melanoma generate such immunogenic neoantigens. Memory CD8+ T cells specific for these neoantigens are preferentially found in 20% of patients with
uveal melanoma bearing SF3B1-mutated
tumors. Single-cell analyses of neoepitope-specific T cells from the blood identified large clonal T-cell expansions, with distinct effector transcription patterns. Some of these expanded
T-cell receptors are also present in the corresponding
tumors. CD8+ T-cell clones specific for the neoepitopes specifically recognize and kill SF3B1-mutated
tumor cells, supporting the use of this new family of neoantigens as therapeutic targets. SIGNIFICANCE: Mutations of the
splicing factor SF3B1 in
uveal melanoma generate shared neoantigens that are uniquely expressed by
tumor cells, leading to recognition and killing by specific CD8 T cells. Mutations in
splicing factors can be sources of new therapeutic strategies applicable to diverse
tumors.This article is highlighted in the In This Issue feature, p. 1861.